Balancing the risks and benefits of prolonged use of infliximab

Schölmerich, Jürgen
April 2009
Gut;Apr2009, Vol. 58 Issue 4, p477
Academic Journal
In this article, the author discusses the result of a study conducted in Leuven, Belgium to determine the efficacy on the use of infliximab in Crohn's disease. The result of the study shows that 614 patients, comprising of individual having luminal disease while 25 percent having fistulising disease, were treated in period of 12 years. Moreover, withdrawal on the use of infliximab accounted to 20 percent due to loss of response while 11 percent had no initial response.


Related Articles

  • Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn's disease patients treated with infliximab. Bellizzi, Anna; Anzivino, Elena; Ferrari, Federica; Nardo, Giovanni; Colosimo, Maria; Fioriti, Daniela; Mischitelli, Monica; Chiarini, Fernanda; Cucchiara, Salvatore; Pietropaolo, Valeria // Journal of NeuroVirology;Aug2011, Vol. 17 Issue 4, p303 

    The recent introduction of monoclonal antibodies in Crohn's disease (CD) management has been associated with the development of serious complications, such as the progressive multifocal leukoencephalopathy (PML), caused by JC polyomavirus (JCV) reactivation. Therefore, the aims of our study have...

  • Remicade Approved for Children With Crohn's Disease.  // FDA Consumer;Jul/Aug2006, Vol. 40 Issue 4, p6 

    The article provides information on Remicade (infliximab), a drug approved by the U.S. Food and Drug Administration (FDA) to treat children with active Crohn's disease, a chronic inflammatory condition of the bowel that can be severely debilitating. Remicade is a genetically engineered...

  • Management of Crohn's disease in poor responders to adalimumab. de Boer, Nanne K. H.; Löwenberg, Mark; Hoentjen, Frank // Clinical & Experimental Gastroenterology;2014, Vol. 7, p83 

    Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we...

  • Infliximab for Crohn's disease. ROSE, VERNA L. // American Family Physician;12/1/1998, Vol. 58 Issue 9, p2175 

    Introduces the monoclonal antibody, infliximab (Remicade), use for the treatment of Crohn's disease. Mechanism of action; Clinical trials; Side effects.

  • Crohn's disease.  // Geriatrics;Dec98, Vol. 53 Issue 12, p16 

    Announces that Infliximab (Remicade), an intravenous (IV) injectable chimeric Immunoglobulin Gamma (IgG) monoclonal antibody, was approved for the treatment of Crohn's disease. Recommended dose; Most common side effects.

  • Infliximab.  // Reactions Weekly;10/16/2010, Issue 1323, p25 

    The article describes the cases of two women who developed Lewis-Summer syndrome (LSS) while receiving treatment with infliximab for Crohn's disease (CD).

  • Infliximab.  // Reactions Weekly;5/15/2010, Issue 1301, p29 

    The article describes the case of two men who developed fulminant legionellosis after being given infliximab as treatment for Crohn's disease.

  • Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease. Feagan, Brian G.; Sandborn, William J.; Hass, Steven; Niecko, Timothy; White, Jeffrey // American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2737 

    OBJECTIVES: We evaluated the effects of treatment on health-related quality of life (HRQoL) during a randomized controlled trial of natalizumab maintenance therapy (ENACT-2) using both disease-specific and generic measures. METHODS: Crohn's disease patients who received natalizumab as induction...

  • Research Brief: Crohn's disease.  // GP: General Practitioner;10/24/2012, p11 

    The article reports that researchers from the University of California, San Diego, have discovered that psoriasis drug, ustekinumab, may be useful in Crohn's disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics